392 related articles for article (PubMed ID: 29873743)
1. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.
Sauerbrei W; Taube SE; McShane LM; Cavenagh MM; Altman DG
J Natl Cancer Inst; 2018 Aug; 110(8):803-811. PubMed ID: 29873743
[TBL] [Abstract][Full Text] [Related]
2. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
Altman DG; McShane LM; Sauerbrei W; Taube SE
PLoS Med; 2012; 9(5):e1001216. PubMed ID: 22675273
[TBL] [Abstract][Full Text] [Related]
3. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
Altman DG; McShane LM; Sauerbrei W; Taube SE
BMC Med; 2012 May; 10():51. PubMed ID: 22642691
[TBL] [Abstract][Full Text] [Related]
4. Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles.
Sekula P; Mallett S; Altman DG; Sauerbrei W
PLoS One; 2017; 12(6):e0178531. PubMed ID: 28614415
[TBL] [Abstract][Full Text] [Related]
5. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.
Mallett S; Timmer A; Sauerbrei W; Altman DG
Br J Cancer; 2010 Jan; 102(1):173-80. PubMed ID: 19997101
[TBL] [Abstract][Full Text] [Related]
6. REporting recommendations for tumour MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Br J Cancer; 2005 Aug; 93(4):387-91. PubMed ID: 16106245
[TBL] [Abstract][Full Text] [Related]
7. REporting recommendations for tumour MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Eur J Cancer; 2005 Aug; 41(12):1690-6. PubMed ID: 16043346
[TBL] [Abstract][Full Text] [Related]
8. Structured reporting to improve transparency of analyses in prognostic marker studies.
Sauerbrei W; Haeussler T; Balmford J; Huebner M
BMC Med; 2022 May; 20(1):184. PubMed ID: 35546237
[TBL] [Abstract][Full Text] [Related]
9. A Survey of the Prevalence and Impact of Reporting Guideline Endorsement in Pathology Journals.
Caron JE; March JK; Cohen MB; Schmidt RL
Am J Clin Pathol; 2017 Oct; 148(4):314-322. PubMed ID: 28967948
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic (STARD) and prognostic (REMARK) studies].
Altman DG; Bossuyt PM; ;
Med Clin (Barc); 2005 Dec; 125 Suppl 1():49-55. PubMed ID: 16464428
[TBL] [Abstract][Full Text] [Related]
11. Reporting recommendations for tumor marker prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
J Natl Cancer Inst; 2005 Aug; 97(16):1180-4. PubMed ID: 16106022
[TBL] [Abstract][Full Text] [Related]
12. REporting recommendations for tumor MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Nat Clin Pract Urol; 2005 Aug; 2(8):416-22. PubMed ID: 16482653
[TBL] [Abstract][Full Text] [Related]
13. REporting recommendations for tumor MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Nat Clin Pract Oncol; 2005 Aug; 2(8):416-22. PubMed ID: 16130938
[TBL] [Abstract][Full Text] [Related]
14. Reporting recommendations for tumor marker prognostic studies.
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
J Clin Oncol; 2005 Dec; 23(36):9067-72. PubMed ID: 16172462
[No Abstract] [Full Text] [Related]
15. REporting recommendations for tumor MARKer prognostic studies (REMARK).
McShane LM; Altman DG; Sauerbrei W; Taube SE; Gion M; Clark GM;
Breast Cancer Res Treat; 2006 Nov; 100(2):229-35. PubMed ID: 16932852
[TBL] [Abstract][Full Text] [Related]
16. Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines.
Jankova L; Dent OF; Molloy MP; Chan C; Chapuis PH; Howell VM; Clarke SJ
Proteomics Clin Appl; 2015 Dec; 9(11-12):1078-86. PubMed ID: 25755195
[TBL] [Abstract][Full Text] [Related]
17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
18. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
19. Publication of tumor marker research results: the necessity for complete and transparent reporting.
McShane LM; Hayes DF
J Clin Oncol; 2012 Dec; 30(34):4223-32. PubMed ID: 23071235
[TBL] [Abstract][Full Text] [Related]
20. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.
Moher D; Hopewell S; Schulz KF; Montori V; Gøtzsche PC; Devereaux PJ; Elbourne D; Egger M; Altman DG;
Int J Surg; 2012; 10(1):28-55. PubMed ID: 22036893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
